Epsolay is owned by Galderma Labs Lp.
Epsolay contains Benzoyl Peroxide.
Epsolay has a total of 6 drug patents out of which 0 drug patents have expired.
Epsolay was authorised for market use on 22 April, 2022.
Epsolay is available in cream;topical dosage forms.
Epsolay can be used as topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older, topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older.
The generics of Epsolay are possible to be released after 18 August, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(5 years from now) | |
US9687465 | GALDERMA LABS LP | Compositions for the treatment of rosacea |
Nov, 2032
(9 years from now) | |
US10945987 | GALDERMA LABS LP | Method for providing early onset of action in the treatment of rosacea |
Feb, 2040
(16 years from now) | |
US10933046 | GALDERMA LABS LP | Method for treatment of rosacea in patients aged 65 years and older |
Feb, 2040
(16 years from now) | |
US11541026 | GALDERMA LABS LP | Method for treatment of rosacea |
Feb, 2040
(16 years from now) | |
US11426378 | GALDERMA LABS LP | Method for long-term treatment of rosacea |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older
Dosage: CREAM;TOPICAL
29
United States
7
IB
5
Canada
3
European Union
2
Israel
1
Korea, Republic of
1
Japan
1
Australia
1
EA
1
South Africa
1
China
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic